Sign in
CARM Stock Price, Chart, Stats & News
Carisma Therapeutics, Inc.
Save
Carisma Therapeutics, Inc. (CARM) does not currently pay a dividend.
–
Market cap
0.03x
Current P/E
–
Forward P/E
CARM chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 98.05% |
Operating margin | 20.61% |
Pretax margin | 15.28% |
Net margin | 15.28% |
Effective tax rate | – |
ROA | 122.70% |
ROE | -28.86% |
D/E | -0.88x |
Interest coverage ratio | – |
CARM valuation
P/E | 0.03x |
P/S | 0.03x |
P/B | -1.59x |
P/CF | -0.06x |
P/FCF | -0.06x |
P/OCF | -0.06x |
PEG | 0.00x |
EV multiple | 0.25x |
About
Carisma Therapeutics, Inc., a biotechnology company, focuses on developing transformative therapies to treat liver fibrosis and cancer in the United States. Its product candidates include CT-2401, which is in preclinical trial for the treatment of liver fibrosis. The company also develops CT-1119, a mesothelin-targeted CAR-Monocyte that is in phase I clinical trial to treat patients with advanced mesothelin-positive solid tumors, including pancreatic cancer, ovarian cancer, lung cancer, mesothelioma, and others.
Similar securities
Based on sector and market capitalization
Report issue